(Reuters) - Wilmington, Massachusetts-based CardioTech said it expects
to gain about $6 million in cash from the sale, after estimated
transaction costs of $500,000 and an escrow funding.
The sale is expected to close on or about July 9,
CardioTech said.
Read more at Reuters.com Mergers News
to gain about $6 million in cash from the sale, after estimated
transaction costs of $500,000 and an escrow funding.
The sale is expected to close on or about July 9,
CardioTech said.
Read more at Reuters.com Mergers News
No comments:
Post a Comment